Eloralintide clinical trials
Eloralintide is named as an intervention in 17 current clinical trials in our USA, Japan, China, Germany, India, South Korea, Taiwan, Australia, Canada, Brazil, Czechia, Spain, UK, Belgium, Poland, Mexico, Denmark, Israel, Singapore, France, Italy, Turkey and Sweden registers. 11 are recruiting patients now. The most common phase is Phase 3. The lead sponsor is Eli Lilly and Company. The most-studied condition is Obesity. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
How Eloralintide works
All drug targets →- OverweightPhase 3
- Obesity disorderPhase 3
- Obstructive sleep apnea syndromePhase 3
- OsteoarthritisPhase 3
- Type 2 diabetes mellitusPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL6068462, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Eloralintide
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Eloralintide
17 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Eloralintide in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Eloralintide. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
J3R-MC-YDAS:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once-Weekly Eloralintide in Adult Participants With Obesity or Overweight, Type 2 Diabetes, and Increased CV Risk
2026-525919-14-00 · CTIS ↗ · Nutritional and Metabolic Diseases
|
Phase 3 | Authorised | Eli Lilly & Co | Spain, Poland, France + 5 more |
Conditions studied with Eloralintide
13 conditionsAll 13 conditions
| Condition (as registered) | Trials |
|---|---|
| Obesity | 13 |
| Overweight | 12 |
| Diabetes Mellitus, Type 2 | 2 |
| Osteoarthritis | 1 |
| Overweight or Obesity | 1 |
| Hepatic Insufficiency | 1 |
| Cardiovascular Diseases | 1 |
| Kidney Disease | 1 |
| Renal Insufficiency Chronic | 1 |
| Kidney Failure, Chronic | 1 |
| Renal Impairment | 1 |
| Healthy Volunteers | 1 |
| Sleep Apnea, Obstructive | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Eli Lilly and Company | 17 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Eloralintide trials
How many clinical trials are testing Eloralintide?
17 current trials in our USA, Japan, China, Germany, India, South Korea, Taiwan, Australia, Canada, Brazil, Czechia, Spain, UK, Belgium, Poland, Mexico, Denmark, Israel, Singapore, France, Italy, Turkey and Sweden registers name Eloralintide (also registered as LY3841136) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Eloralintide trials recruiting patients?
Yes. 11 of the 17 trials are recruiting: 10 with sites in USA, 5 with sites in Japan, 5 with sites in China, 5 with sites in Germany, 4 with sites in India, 4 with sites in South Korea, 5 with sites in Taiwan, 3 with sites in Australia, 3 with sites in Canada, 3 with sites in Brazil, 3 with sites in Czechia, 3 with sites in Spain, 2 with sites in UK, 3 with sites in Belgium, 2 with sites in Poland, 2 with sites in Mexico, 1 with sites in Denmark, 1 with sites in Israel, 1 with sites in Singapore and 1 with sites in Sweden. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Eloralintide clinical trials?
The lead sponsor is Eli Lilly and Company. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Eloralintide works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Eloralintide works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Eloralintide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.